retatrutide type 2 diabetes trial results 2024 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Triple hormone receptor agonist retatrutide

Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21

Diabetic retinopathy: In people with diabetes, rapid improvements in glycaemic control with GLP-1 receptor agonists may be associated with temporary worsening of diabetic retinopathy

California, Delaware, Maryland, Massachusetts, New Jersey, New York, and Virginia have laws requiring ACA Marketplace plans to cover FDA-approved obesity medications

We're constantly tracking the latest shifts in food industry trends, operational insights, and practical strategies that help food professionals thrive